中红普林医疗用品股份有限公司 2022 年第一季度报告全文 证券代码：300981 证券简称：中红医疗 公告编号：2022-026 中红普林医疗用品股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 √ 适用 □ 不适用 单位：元 | 项目 | 本报告期金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益（包括已计提资产减值准备的冲销部分） | -322,837.48 | | | 计入当期损益的政府补助（与公司正常经营业务密切相关，符 合国家政策规定、按照一定标准定额或定量持续享受的政府补 | 5,209,716.28 | | | 助除外） | | | | ...

Financial Performance - The company's operating revenue for 2021 was approximately CNY 4.91 billion, an increase of 2.74% compared to CNY 4.78 billion in 2020 [20]. - The net profit attributable to shareholders for 2021 was approximately CNY 2.34 billion, a decrease of 12.07% from CNY 2.66 billion in 2020 [20]. - The net profit after deducting non-recurring gains and losses was approximately CNY 2.25 billion, down 15.19% from CNY 2.65 billion in 2020 [20]. - The total assets at the end of 2021 reached approximately CNY 7.15 billion, a significant increase of 94.73% from CNY 3.67 billion at the end of 2020 [20]. - The net assets attributable to shareholders at the end of 2021 were approximately CNY 6.55 billion, up 156.45% from CNY 2.56 billion at the end of 2020 [20]. - The basic earnings per share for 2021 were CNY 15.33, a decrease of 28.06% compared to CNY 21.31 in 2020 [20]. - The cash flow from operating activities for 2021 was approximately CNY 2.36 billion, down 13.13% from CNY 2.72 billion in 2020 [20]. - The company achieved a total operating revenue of ¥4,909,310,936.58, representing a year-on-year increase of 2.74% [66]. - The net profit attributable to shareholders was ¥2,341,903,879.36, a decrease of 12.07% compared to the previous year [66]. Dividend and Profit Distribution - The company reported a profit distribution plan, proposing a cash dividend of 30.00 RMB per 10 shares based on a total of 166,670,000 shares [5]. - The cash dividend distribution represents 100% of the total distributable profit of 3,779,004,979.13 RMB [175]. - The total number of shares for the dividend distribution is based on 166,670,000 shares, with no stock dividends issued [174]. Market Expansion and Strategy - The company is focused on expanding its market presence and enhancing its product offerings in the medical supplies sector [5]. - The company plans to expand into other medical device fields, medical services, and digital healthcare, leveraging both organic growth and acquisitions [30]. - The company is actively pursuing market expansion strategies to enhance its competitive position [156]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years [145]. - A strategic acquisition of a local competitor is anticipated to enhance the company's distribution network and increase market penetration [145]. Research and Development - The company is actively investing in research and development for new medical products and technologies [5]. - The company emphasizes R&D, collaborating with institutions like the Chinese Academy of Sciences to innovate in polymer materials and production processes [47]. - The company's R&D investment amounted to ¥177,758,360.52 in 2021, representing 3.62% of total revenue, an increase from 3.27% in 2020 [82]. - Research and development expenditures have increased by 25%, reflecting the company's commitment to innovation [149]. Production Capacity and Operations - The company has a production capacity of 22.5 billion disposable protective gloves, ranking among the top in the domestic industry [34]. - The company has added significant production capacity, including a new project in Tangshan with an annual output of 3 billion nitrile gloves and another in Jiangxi with a capacity of 5 billion nitrile gloves, enhancing its competitive edge [53]. - The company plans to invest a total of ¥1.866 billion in a new medical-grade glove production project in Cangxi County, Guangyuan City, Sichuan Province [62]. - The company is expanding its production capacity with the construction of 40 nitrile glove production lines in partnership with local governments [167]. Governance and Compliance - The company is under the supervision of the Xiamen State-owned Assets Supervision and Administration Commission [12]. - The report outlines the company's governance structure and compliance with regulatory requirements [5]. - The company maintains a complete and independent operational capability, with no reliance on related party transactions for its main business income and profits [128]. - The company has committed to transparent information disclosure, ensuring all investors have equal access to relevant information [124]. Environmental Responsibility - The company has implemented various pollution control technologies to ensure stable compliance with emission standards [188]. - The company has established a wastewater treatment plant that meets discharge standards and is equipped with online monitoring systems [189]. - The company has not experienced any environmental pollution incidents during the reporting period [189]. - The company plans to invest in a medical-grade glove project in Sichuan Province, utilizing clean energy to reduce carbon emissions compared to fossil fuels [193]. Employee Management and Development - The company has established a systematic training management system, conducting at least one training session every three months for all employees [173]. - The company has implemented a market-oriented salary survey and reformed its salary mechanism to optimize incentive plans, establishing a fair and competitive salary distribution system [171]. - The total number of employees at the end of the reporting period was 3,678, with 2,624 in the parent company and 1,054 in major subsidiaries [169]. - The company has established a performance evaluation system to motivate employees and align business objectives [171]. Financial Management - The company has established five dedicated accounts for the management of raised funds, ensuring strict approval procedures for their use [100]. - The company has maintained a strong financial position, ensuring the protection of shareholder and creditor rights through transparent operations and communication [194]. - The financial budget report for 2021 was approved, indicating a strategic focus on financial planning [156]. - The company has not reported any significant changes in its investment strategy or major equity investments during the reporting period [93].

中红普林医疗用品股份有限公司 2021 年第三季度报告 中红普林医疗用品股份有限公司 2021 年第三季度报告 2021-053 2021 年 10 月 1 中红普林医疗用品股份有限公司 2021 年第三季度报告 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增 | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | | | | 减 | | 同期增减 | | 营业收入（元） | 687,701,851.63 | -61.90% | 4,334,692,590.58 | 47.41% | | 归属于上市公司股东的 净利润（元） | 234,708,423.62 | -79.41% | 2,323,537,036.31 | 44.94% | | 归属于上市公司股东的 扣除非经常性损益的净 | ...

Financial Performance - The company's operating revenue for the reporting period reached ¥3,646,990,738.95, representing a 221.17% increase compared to ¥1,135,521,879.99 in the same period last year[23]. - The net profit attributable to shareholders was ¥2,088,828,612.69, a significant increase of 351.09% from ¥463,066,580.78 in the previous year[23]. - The net cash flow from operating activities was ¥1,681,854,554.29, up 103.27% from ¥827,410,310.85 in the same period last year[23]. - The total assets at the end of the reporting period were ¥7,270,560,719.69, a 97.96% increase from ¥3,672,716,594.29 at the end of the previous year[24]. - The net assets attributable to shareholders increased by 155.93% to ¥6,540,793,361.20 from ¥2,555,731,004.38 at the end of the previous year[24]. - Basic earnings per share rose to ¥15.0394, reflecting a 305.98% increase from ¥3.7045 in the same period last year[23]. - The weighted average return on equity was 58.02%, down from 66.21% in the previous year, indicating a decrease of 8.19%[23]. - The company achieved a revenue of approximately CNY 3.65 billion, representing a year-on-year growth of 221.17%[49]. - The net profit attributable to shareholders reached approximately CNY 2.09 billion, marking a year-on-year increase of 351.09%[49]. Cash Management and Dividends - The company reported a cash dividend of 15 RMB per 10 shares, based on a total of 166,670,000 shares[4]. - The total undistributed profits of the company as of June 30, 2021, amount to 4,351,323,734.05 yuan, with the parent company's undistributed profits at 3,783,848,366.91 yuan[108]. - The cash dividend distribution accounts for 100% of the total profit distribution amount, ensuring compliance with the company's profit distribution policy[107]. - The company’s cash management of idle raised funds has generated interest income of RMB 2,459,564.00[84]. Risk Management and Compliance - The company emphasizes the importance of risk awareness regarding future plans and forecasts, as outlined in the risk management section of the report[4]. - The company faces risks from international market fluctuations, particularly due to political factors affecting trade with major markets like the US and Europe[96]. - The company is addressing currency fluctuation risks by monitoring the foreign exchange market and engaging in foreign exchange derivative transactions[98]. - The company has established emergency response plans for environmental incidents, which have been reviewed and filed[117]. - All subsidiaries have complied with environmental laws and regulations, with no administrative penalties for environmental issues during the reporting period[119]. Research and Development - The company emphasizes research and development, establishing a complete R&D incentive mechanism and collaborating with well-known domestic institutions for innovation[39]. - The R&D process includes multiple stages such as project application, research, pilot testing, and effect tracking to ensure scientific and reasonable development[40]. - The company holds 39 patents and has established the Hebei Medical Glove Technology Innovation Center, indicating a strong commitment to R&D and innovation[52]. - The company has developed multiple high-value-added gloves during the reporting period, with some already launched in the market, showcasing its focus on new product development[52]. Market Expansion and Strategy - The company has outlined its strategies for market expansion and product development in the upcoming sections of the report[6]. - The company is actively expanding into new markets, including South America, the Middle East, and Russia, while strengthening partnerships with major hospitals in China[51]. - The company has adopted a "high-end, differentiated" strategy to maintain competitiveness amid increasing market competition[44]. - The company is actively pursuing strategies for market expansion and potential mergers and acquisitions[145]. Environmental Responsibility - The company has highlighted its commitment to social responsibility and environmental considerations in its operations[5]. - The company is committed to environmental protection and is enhancing its facilities to comply with stricter environmental regulations[101]. - The company has installed online monitoring systems for emissions and has implemented advanced pollution control technologies for both air and wastewater[114]. - The company donated a total of 300,000 PVC and nitrile gloves to aid COVID-19 prevention efforts in Shijiazhuang and Xingtai in January 2021[120]. Corporate Governance - The board of directors confirmed that all members attended the meeting to review the report, ensuring accountability for the report's accuracy[3]. - The company held five temporary shareholder meetings in 2021, with investor participation rates ranging from 72.42% to 100%[105]. - The company has maintained stable operations without changes in its board of directors or senior management during the reporting period[106]. - The company has not engaged in any significant related party transactions during the reporting period[130]. Production Capacity and Operations - The company has a total production capacity of approximately 19.5 billion gloves, with 9 billion nitrile gloves, 8 billion PVC gloves, and 2.5 billion PE gloves[42]. - The company plans to add 9.5 billion units of new production capacity in the second half of the year, including 3 billion nitrile gloves and 5 billion nitrile gloves from a subsidiary[50]. - The company employs a "sales-driven production" model, adjusting production plans based on sales orders and maintaining appropriate inventory levels to meet customer demands[36]. - The company is investing in automation to mitigate rising labor costs and enhance operational efficiency[100].

Financial Performance - Revenue for Q1 2021 reached ¥2,273,468,425.20, a significant increase of 588.22% compared to ¥330,338,183.75 in the same period last year[8] - Net profit attributable to shareholders was ¥1,402,440,132.02, representing a remarkable growth of 2,437.40% from ¥55,270,819.57 year-on-year[8] - Basic earnings per share increased to ¥11.2195, a rise of 2,437.20% compared to ¥0.4422 in the same period last year[8] - Operating profit for Q1 2021 was CNY 1,679,368,813.38, compared to CNY 65,380,732.25 in Q1 2020, indicating a substantial increase of about 2,426.5%[42] - The company achieved a total comprehensive income of CNY 1,402,698,311.90 in Q1 2021, compared to CNY 55,381,009.26 in the same period last year, indicating a growth of approximately 2,430.5%[43] Cash Flow - The net cash flow from operating activities was ¥979,620,507.97, up 815.11% from ¥107,049,720.84 in the previous year[8] - Total cash inflow from operating activities amounted to ¥1,874,877,253.99, compared to ¥413,328,453.40 in the prior period, indicating a rise of about 353%[48] - Cash outflow from operating activities was ¥895,256,746.02, up from ¥306,278,732.56, reflecting an increase of approximately 193%[49] - The cash balance at the beginning of the period was ¥1,127,619,527.89, compared to ¥29,586,459.76 in the previous period, showing a substantial increase of about 3,706%[50] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,007,990,342.22, reflecting a 36.36% increase from ¥3,672,716,594.29 at the end of the previous year[8] - The company's total liabilities decreased to CNY 1,049,561,025.94 from CNY 1,116,985,589.91, a reduction of about 6%[35][36] - The total equity attributable to shareholders increased by 54.88% to ¥3,958,429,316.28 from ¥2,555,731,004.38 at the end of the previous year[8] - The company's current assets totaled CNY 3,596,682,177.29 as of March 31, 2021, compared to CNY 2,662,501,350.08 at the end of 2020, indicating a rise of about 35%[33][36] Investments and Projects - The company plans to invest approximately ¥50 billion in a new high-end medical glove project, with an expected annual production capacity of 300 billion gloves[24] - The company has signed agreements to establish 40 production lines for nitrile gloves in Guangxi and Hubei, expected to add 260 billion gloves in capacity by the end of 2022[22] - The company has increased its investment in construction projects, with construction in progress rising by 87.10% to ¥596,717,206.72[16] Research and Development - R&D expenses increased by 61.98% to ¥2,776,590.10, indicating a focus on innovation and product development[17] - Research and development expenses for Q1 2021 were CNY 2,776,590.10, compared to CNY 1,714,108.56 in Q1 2020, showing an increase of approximately 62%[42] Risks and Challenges - The company is facing risks from international trade disruptions, raw material price fluctuations, and increased market competition[20][21] - The company has not reported any significant changes in its top five customers, indicating stable customer relationships[19] Stock Market Activity - The company has successfully completed its IPO on the Shenzhen Stock Exchange, increasing its total share capital from 125 million to 166.67 million shares[22]